PLEURAL BIOPSY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Pleural Biopsy Market Size and Forecast – 2025 to 2032

The Global Pleural Biopsy Market is estimated to be valued at USD 330.4 Mn in 2025 and is expected to reach USD 503.4 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032. This steady growth is driven by the increasing prevalence of pleural diseases, advancements in biopsy techniques, and rising demand for minimally invasive surgeries across healthcare settings worldwide.

Key Takeaways of the Global Pleural Biopsy Market

• In 2025, by product type, biopsy needles and instruments account for the largest market share at an estimated market share of 40.2%, supported by their vital role in minimally invasive pleural tissue sampling and ensuring diagnostic accuracy.
• By technique, needle biopsy (closed needle/Abrams needle) is expected to dominate with a 44.3% share, attributed to its minimally invasive approach, cost-effectiveness, and procedural simplicity.
• By diagnostic application, malignant pleural effusion and pleural malignancies (including mesothelioma and metastatic cancers) lead with an estimated 36.8% market share, fueled by the increasing demand for accurate diagnostic tools in oncology.
• North America is expected to lead the market, holding a share of 37.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 23.3% in 2025.

Market Overview

A significant market trend is the shift towards the adoption of image-guided and needle-based biopsy methods, which offer higher accuracy and reduced patient trauma. Additionally, growing investments in research and development, along with enhanced awareness among clinicians and patients about early diagnosis, are further fueling market expansion. Integration of innovative technologies such as digital imaging and robotics is also expected to shape the future landscape of the pleural biopsy market.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Pleural Biopsy Market Insights, By Product Type – Biopsy needles and instruments segment is dominant due to their critical role in minimally invasive tissue sampling and diagnostic accuracy

In terms of product type, biopsy needles and instruments contribute the highest share of the market with an estimated market share of 40.2% in 2025 owing to their critical role in minimally invasive pleural tissue sampling and diagnostic accuracy. Biopsy needles and instruments are the primary tools used in extracting pleural tissue samples, which are essential for the accurate diagnosis of various pleural diseases.

Their design has evolved to enhance precision, safety, and patient comfort, making them the preferred choice among healthcare providers. One of the major factors driving this segment’s dominance is the widespread clinical acceptance of needle biopsy techniques as a relatively simple and cost-effective approach compared to more invasive surgical procedures.

Another key growth driver for biopsy needles and instruments is the continuous innovation in needle technology, including the development of finer gauge needles and improved tip designs that minimize tissue trauma while improving sample quality.

In August 2022, Mammotome, a global leader in breast care technologies, announced the launch of its Mammotome DualCore Dual Stage Core Biopsy System, the company’s first dual-stage core biopsy device. Expanding its ultrasound-guided breast biopsy portfolio which also includes the Mammotome Elite Tetherless VABB and Mammotome Revolve Dual VABB the new system offers three programmable firing modes, one-handed operation, and an ergonomic design to improve precision and patient comfort.

Pleural Biopsy Market Insights, By Technique – Needle biopsy (closed needle/Abrams needle) is dominant due to its minimally invasive nature and cost-effectiveness

In terms of technique, needle biopsy (closed needle/Abrams needle) is expected to contribute the highest share of the market, accounting for 44.3% in 2025 due to its minimally invasive nature, cost-effectiveness, and procedural simplicity. Needle biopsy techniques have become the cornerstone for initial pleural evaluation because they allow clinicians to obtain diagnostic samples without the need for hospitalization or general anesthesia, unlike more invasive surgical or thoracoscopic methods. The closed needle biopsy, in particular, has longstanding clinical validation, which enhances physician confidence in its diagnostic utility.

The preference for needle biopsy also stems from its ability to be performed in outpatient settings, making it more convenient for both patients and healthcare providers. This technique's lower risk profile compared to thoracoscopic or open surgical biopsies makes it the favored initial diagnostic step, especially in resource-constrained environments where advanced surgical infrastructure may be limited. Furthermore, advancements in needle biopsy devices, including the use of imaging guidance during the procedure, have significantly improved tissue sampling accuracy, thereby reducing the need for repeat biopsies.

Pleural Biopsy Market Insights, By Diagnostic Application – Malignant pleural effusion and pleural malignancies is dominant due to the rising global cancer burden

 In terms of diagnostic application, the malignant pleural effusion and pleural malignancies (e.g., mesothelioma, metastatic cancers) segment is expected to contribute the highest share of the market with 36.8% in 2025, driven by the growing need for precise diagnostic tools in oncology. Malignant pleural effusions serve as a common complication in advanced cancers, often requiring confirmatory biopsy for appropriate staging and treatment planning. The high morbidity and mortality associated with pleural malignancies necessitate timely and accurate tissue diagnosis, which propels the use of pleural biopsy devices across healthcare settings worldwide.

The increasing global burden of lung cancer, mesothelioma, and metastatic pleural disease is a major factor behind the rising demand for biopsy solutions in this diagnostic category. With emerging targeted therapies and immunotherapies, oncologists require more precise histological and molecular diagnostic information from pleural samples to tailor treatments effectively. This demand has encouraged technological advancement in biopsy tools designed to obtain larger and higher quality tissue specimens, critical for advanced diagnostic testing.

Role of Artificial Intelligence (AI) on the global pleural biopsy market

• Artificial Intelligence (AI) is reshaping the global pleural biopsy market by streamlining diagnostic processes, reducing human error, and enabling faster, more accurate decision-making. AI-powered imaging tools are enhancing the detection of pleural abnormalities by analyzing CT scans, chest X-rays, and ultrasound images with greater precision than conventional methods. This not only improves early diagnosis rates but also reduces the need for invasive procedures, ultimately lowering healthcare costs and improving patient outcomes. Predictive analytics further supports clinicians by forecasting disease progression, guiding biopsy site selection, and tailoring treatment strategies to individual patients. For example, companies like Guardant Health and Intuitive Surgical are integrating AI-driven platforms into biopsy and robotic-assisted procedures to improve accuracy, efficiency, and yield, making minimally invasive pleural biopsy more effective and accessible across healthcare systems.
• Beyond diagnostics, AI is creating new business opportunities in automation, operational efficiency, and patient-centric services within the pleural biopsy ecosystem. Automated pathology workflows, AI-assisted cytology, and machine learning models in histopathology are accelerating sample analysis and reducing turnaround times, which directly benefits hospitals and diagnostic centers. At the strategic level, AI enables providers to adopt data-driven business models, improve scalability, and strengthen competitive positioning through innovations like personalized biopsy guidance systems and remote decision-support platforms. However, while AI offers transformative potential, challenges remain around implementation costs, data privacy, and over-reliance on algorithms. To succeed, companies in the pleural biopsy market must balance human expertise with AI adoption—leveraging automation and predictive insights for long-term growth while ensuring ethical use and robust clinical validation of AI systems.

Regional Insights

To learn more about this report, Download Free Sample

North America Pleural Biopsy Market Analysis and Trends

In North America, the dominance in the global pleural biopsy market is driven by a highly developed healthcare infrastructure with an estimated share of 37.3% in 2025, strong presence of leading medical device manufacturers, and significant investment in biomedical research. The region benefits from advanced hospital settings equipped with state-of-the-art diagnostic tools and minimally invasive procedural capabilities. Government policies in countries such as the United States and Canada emphasize early detection and precision medicine, fueling demand for sophisticated biopsy techniques. Additionally, regulatory frameworks like the U.S. FDA’s robust approval process help ensure device safety and efficacy, reinforcing market confidence.

In October 2023, DELFI Diagnostics, a U.S.-based developer of accessible blood-based cancer detection tests, announced the commercial launch of FirstLook Lung, a routine blood test that enhances lung cancer screening by analyzing cell-free DNA fragments with whole-genome machine learning. The test, designed to complement low-dose CT scans, delivers personalized results with a 99.7% negative predictive value, helping identify patients at risk for lung cancer, including early-stage disease.

Asia Pacific Pleural Biopsy Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the pleural biopsy market with a share of 23.3% in 2025, underpinned by increasing healthcare expenditure, rising prevalence of pulmonary diseases, and expanding healthcare infrastructure in emerging economies. Countries like China, India, Japan, and South Korea are investing heavily in healthcare modernization and expanding their diagnostic services ecosystem. Government initiatives aimed at universal health coverage and improved diagnostic capabilities are fostering adoption of advanced biopsy modalities. The expanding presence of international and local medical device companies, including Olympus Corporation, Hologic, and Becton Dickinson, further catalyzes market growth by introducing cost-effective and region-specific solutions. Trade liberalization and improved supply chain logistics are also enabling faster market penetration in remote and underserviced areas.

Pleural Biopsy Market Outlook for Key Countries

U.S. Pleural Biopsy Market Trends

The U.S. pleural biopsy market remains at the forefront of technological innovation in pleural biopsy, supported by its strong R&D infrastructure and sophisticated healthcare delivery systems. Renowned medical device manufacturers such as Boston Scientific and Medtronic actively engage in developing minimally invasive biopsy tools and navigation systems, enhancing diagnostic accuracy. Moreover, emphasis on personalized healthcare and early disease detection, along with favorable reimbursement policies, drives demand for advanced pleural biopsy techniques within hospital networks and specialty clinics.

In June 2020, NeoGenomics, a U.S.-based cancer genetic testing company, launched three liquid biopsy tests on June 29, 2020, for lung, breast, and solid tumors, giving results in under seven days when tissue samples are hard to get. In partnership with Inivata, a liquid biopsy specialist, it also offers the InVisionFirst-Lung test for advanced lung cancer, which checks 37 key genes and is covered by Medicare and private insurance.

U.K. Pleural Biopsy Market Trends

The U.K. pleural biopsy market is witnessing steady adoption of advanced, minimally invasive diagnostic techniques, with a strong shift toward image-guided procedures such as ultrasound and CT-guided biopsies. Hospitals and NHS trusts are increasingly favoring ultrasound-guided approaches for their cost-effectiveness, portability, and real-time imaging advantages, particularly in outpatient and bedside settings. At the same time, CT-guided biopsies are being utilized for complex or deep-seated pleural lesions, improving diagnostic accuracy.

In June 2023, the U.K.’s Welsh government, through its All-Wales Medical Genomic Service (AWMGS), the national provider of genetic services under NHS Wales, launched the QuicDNA program to accelerate lung cancer diagnosis using liquid biopsies. In collaboration with Illumina, a global leader in next-generation sequencing technologies, and 13 other organizations, the initiative will deliver comprehensive genomic profiling for 1,260 patients across Wales’ seven health boards, marking a significant step forward for lung cancer diagnostics in the U.K.

Germany Pleural Biopsy Market Trends

Germany continues to lead the Europe pleural biopsy market with its advanced healthcare infrastructure and strong emphasis on diagnostic precision. Regulatory support through stringent standards and investment in medical technology innovation fosters market growth. Established companies like Olympus and KARL STORZ maintain a solid foothold by supplying high-quality biopsy instruments and endoscopic systems tailored to the demands of German hospitals and specialized clinics. Coordinated healthcare initiatives ensure widespread access to cutting-edge diagnostic options across the country.

In May 2024, Guardant Health, Inc., a U.S.-based precision oncology company, announced on May 21, 2024, that its Guardant360 CDx liquid biopsy test received EU IVDR certification from TÜV SÜD, a Germany-based notified body for product safety and certification. The NGS-based blood test supports comprehensive genomic profiling for all solid cancers, including its growing relevance in thoracic oncology and pleural disease diagnostics, alongside companion diagnostic use in advanced lung and breast cancers.

India Pleural Biopsy Market Trends

India’s pleural biopsy market demonstrates significant potential, driven by expanding healthcare access and increased government funding for diagnostic services. The rise in pulmonary ailments and growing focus on minimally invasive procedures promote the adoption of pleural biopsy in both urban and rural healthcare centers. Partnerships between multinational corporations such as Hologic and local manufacturers facilitate the introduction of cost-effective biopsy technologies suited to the Indian market. Government policies aimed at strengthening primary healthcare infrastructure further support the gradual uptake of innovative diagnostic techniques.

In April 2022, Yashoda Hospitals, a leading multi-specialty healthcare group in India, introduced Cone Beam CT Guided Lung Biopsy at its Secunderabad unit, enabling doctors to diagnose lung cancer at a very early stage. The advanced procedure, performed by the hospital’s Interventional Pulmonology team, is considered a gold standard for detecting lung nodules and offers patients the chance for timely surgical intervention, addressing the global challenge where most lung cancer cases are detected late.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In January 2024, Penn Medicine, a leading U.S. academic medical center, introduced the Ion Endoluminal System by Intuitive Surgical, a global pioneer in robotic-assisted surgical technologies, to shorten the lung cancer diagnosis journey through minimally invasive robotic bronchoscopy. The system’s thin, flexible catheter—guided by CT scans and shape-sensing technology—can access all 18 lung segments and reach tiny peripheral nodules with precision.
• In December 2024, St Richard’s Hospital, part of University Hospitals Sussex NHS Foundation Trust in the U.K., launched a new Endobronchial Ultrasound (EBUS) service to speed up the diagnosis and staging of lung cancer. The minimally invasive procedure uses a flexible tube with an ultrasound tool to examine lungs and chest lymph nodes, offering quicker, safer, and more accurate results compared to traditional biopsies.
• In October 2024, Cook County Health, a leading U.S. public health system, launched the Intuitive Surgical ION Navigational Bronchoscopy platform at Stroger Hospital. Intuitive Surgical, a global leader in robotic surgery, developed this system to make lung cancer biopsies safer, less invasive, and more accurate, helping patients get earlier diagnoses and faster treatment.
• In January 2023, BioMark Diagnostics Inc., a Canada-based liquid biopsy company focused on early cancer detection, announced on January 11, 2023, that enrollment in its pivotal lung cancer screening study at the Quebec Heart and Lung Institute surpassed 1,000 participants in under a year, with a target of 4,000 across eight Quebec hospitals. The study combines BioMark’s metabolomics liquid biopsy with radiomics and genetic biomarkers to improve screening accuracy.

Top Strategies Followed by Global Pleural Biopsy Market Players

• The competitive landscape of the global pleural biopsy market is shaped by a diverse array of players ranging from established multinational corporations to emerging mid-level companies and agile small-scale enterprises. Leading market players typically invest heavily in research and development (R&D) to deliver innovative, high-performance products that address evolving clinical needs. These companies focus on advancing biopsy technologies to improve diagnostic accuracy, patient safety, and procedural efficiency.
  • In September 2021, Johnson & Johnson, a global healthcare leader, and Mauna Kea Technologies, a France-based company specializing in real-time in vivo cellular imaging, launched a study to evaluate Cellvizio, Mauna Kea’s flexible microscope that attaches to an endoscope to guide lung cancer biopsies. The technology provides real-time video of peripheral lung nodules—areas traditionally hard to reach with standard bronchoscopies—helping surgeons improve diagnostic yield and accuracy in detecting early-stage cancerous tumors.

• Mid-level players in the pleural biopsy market are increasingly focusing on cost-effective devices and consumables that balance quality with affordability, particularly to serve hospitals and clinics in developing regions where budget constraints limit access to advanced technologies. These companies frequently collaborate with technology providers or contract manufacturers to expand their reach and maintain performance standards while offering economically viable options
  • In July 2022, Intuitive Surgical, a leader in robotic-assisted surgery, announced that it had received U.S. FDA clearance to integrate Siemens Healthineers’ Cios Spin mobile C-arm imaging system into its Ion robotic platform. This integration will enable minimally invasive lung biopsies using advanced imaging technology. While top-tier players like Intuitive focus on high-tech integrations to enhance diagnostic precision and yield by up to 10%, mid-level manufacturers emphasize affordability, thereby ensuring that pleural biopsy solutions remain accessible across diverse healthcare settings worldwide.

• Small-scale players in the global pleural biopsy market navigate competition by honing in on specialized features or innovative product attributes tailored to specific clinical needs. This niche-focused strategy allows them to differentiate themselves from mass-market offerings by addressing unique user requirements such as enhanced maneuverability, minimally invasive techniques, or integration with advanced imaging modalities. By adopting cutting-edge technologies–for example, incorporating AI-driven diagnostics or novel biomaterials–these smaller companies maintain relevance in a rapidly evolving market.
  • In September 2021, MountainView Hospital, a leading healthcare facility in the U.S., introduced the ION robotic-assisted bronchoscopy platform from Intuitive Surgical, a global pioneer in robotic surgery, to improve early detection of lung cancer through minimally invasive biopsies. The new procedure complements MountainView’s Incidental Lung Nodule Detection and Low Dose CT Lung Screen Programs, enhancing early-stage diagnosis and treatment.

Market Report Scope

Pleural Biopsy Market Report Coverage

Pleural Biopsy Market Dynamics

To learn more about this report, Download Free Sample

Pleural Biopsy Market Driver - Rising Prevalence of Lung Diseases and Pleural Disorders

The increasing incidence of lung diseases and pleural disorders worldwide is significantly fueling the demand for pleural biopsy procedures. Conditions such as pleural effusion, malignant mesothelioma, tuberculosis-related pleuritis, and various other infectious or inflammatory pleural abnormalities require accurate and early diagnosis to guide appropriate treatment plans. Pleural biopsy plays a critical role in differentiating between benign and malignant pleural diseases, enabling clinicians to obtain tissue samples directly from the pleura with minimally invasive techniques. The rise in respiratory conditions attributable to factors like environmental pollution, smoking, occupational hazards, and aging populations contributes directly to the growing patient pool requiring diagnostic evaluation of pleural lesions.

In August 2025, WHO/Europe and the European Respiratory Society report that chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease affect over 81 million people in the region, costing USD 21 billion annually. COPD causes 80% of CRD-related deaths, while asthma drives high youth hospitalizations. The report highlights underdiagnosis and weak policy focus, urging stronger health systems, better training, more research, and preventive measures against smoking, pollution, and unsafe workplaces.

Pleural Biopsy Market Opportunity - Increasing Adoption of Image-Guided Pleural Biopsy Techniques

The global pleural biopsy market is experiencing significant growth driven by the increasing adoption of image-guided pleural biopsy techniques, particularly ultrasound and computed tomography (CT)-guided procedures. These advanced imaging modalities offer enhanced precision and safety in obtaining pleural tissue samples, enabling accurate diagnosis of pleural diseases such as malignancies, infections, and inflammatory conditions. Ultrasound-guided pleural biopsy is gaining popularity due to its real-time imaging capability, cost-effectiveness, portability, and lack of radiation exposure, making it particularly suitable for bedside or outpatient settings. Similarly, CT-guided biopsies are preferred for targeting lesions that are inaccessible or poorly visualized with ultrasound, ensuring higher diagnostic yields, especially for deep-seated or complex pleural abnormalities.

The integration of these image-guided techniques reduces complication rates like pneumothorax and bleeding compared to blind or thoracoscopic biopsy methods, improving overall patient outcomes. For example, Olympus Corporation is a leading global player in endoscopy and medical imaging devices. Olympus offers advanced thoracoscopes and ultrasound endoscopy systems widely used for real-time image-guided pleural and lung biopsies, supporting minimally invasive diagnostics.

Analyst Opinion (Expert Opinion)

• The global pleural biopsy market is steadily gaining traction as healthcare systems worldwide push for earlier and more accurate diagnosis of pleural diseases. Rising incidences of lung cancer and tuberculosis, combined with the growing demand for minimally invasive procedures, are driving adoption of advanced biopsy techniques. Technological innovations such as image-guided thoracoscopy, robotic-assisted systems, and AI-enabled navigation are improving diagnostic yield and patient outcomes, while regulatory support and reimbursement in developed markets are encouraging uptake. However, challenges such as the shortage of skilled specialists, procedural risks, and high costs of advanced systems remain hurdles. At the same time, emerging opportunities in developing regions, where access to affordable diagnostics is expanding, provide significant potential for future growth.
• In recent years, knowledge-sharing platforms have also played a crucial role. International gatherings such as the World Conference on Lung Cancer, CHEST Annual Meeting, and the European Respiratory Society Congress have brought together clinicians, researchers, and industry players to discuss advancements in thoracic oncology and interventional pulmonology, influencing both policy and practice. Market activity has been evident in initiatives like Cook County Health’s launch of the Intuitive ION robotic bronchoscopy platform, the Welsh government’s QuicDNA liquid biopsy programme, and St Richard’s Hospital’s adoption of endobronchial ultrasound to cut waiting times. These real-world projects reflect how collaborations between hospitals, technology providers, and governments are reshaping diagnostic pathways, making pleural biopsy more accessible and effective for patients across regions.

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Biopsy Needles and Instruments
  • Thoracoscopes and Accessories
  • Imaging and Guidance Systems
  • Ancillary Equipment (suction devices, forceps, kits, etc.)
• Technique Insights (Revenue, USD Mn, 2020 - 2032)
  • Needle Biopsy (Closed Needle/Abrams Needle)
  • Thoracoscopic Pleural Biopsy (Medical Thoracoscopy/VATS)
  • Open Surgical Pleural Biopsy
• Diagnostic Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Malignant Pleural Effusion and Pleural Malignancies (e.g., mesothelioma, metastatic cancers)
  • Infectious Pleural Diseases (e.g., tuberculosis, bacterial/fungal pleuritis)
  • Inflammatory and Autoimmune Conditions (e.g., rheumatoid pleuritis, lupus)
  • Other Idiopathic or Unexplained Pleural Effusions
• Guidance Method Insights (Revenue, USD Mn, 2020 - 2032)
  • Image-Guided (CT-guided, Ultrasound-guided)
  • Non-Guided
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Academic and Research Institutes
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Olympus Corporation
  • Boston Scientific Corporation
  • Cook Medical
  • CONMED Corporation
  • Medtronic plc
  • Braun Melsungen AG
  • Hologic Inc.
  • BD (Becton, Dickinson and Company)
  • FUJIFILM Holdings Corporation
  • KARL STORZ SE & Co. KG
  • Ethicon (Johnson & Johnson)
  • Argon Medical Devices
  • Richard Wolf GmbH
  • Smiths Medical

Sources

Primary Research Interviews

Industry Stakeholders

• Pulmonologists (specialists in pleural diseases)
• Thoracic Surgeons
• Medical Device Manufacturers (biopsy needles, thoracoscopes)
• Hospital Procurement Managers
• Clinical Pathologists
• Radiologists specializing in image-guided biopsies

End Users

• Patients undergoing pleural biopsy procedures
• Hospitals (public & private)
• Diagnostic & Imaging Centers
• Ambulatory Surgical Centers
• Academic Medical Institutes
• Cancer Specialty Clinics

Government and International Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC, U.S.)
• National Cancer Institute (NCI, U.S.)
• European Centre for Disease Prevention and Control (ECDC)
• Global Cancer Observatory (GLOBOCAN – IARC/WHO)
• National Health Service (NHS, UK)

Trade Publications

• MedTech Dive
• Diagnostics World
• Clinical Lab Products Magazine
• Medical Device Network
• MedPage Today
• Fierce Biotech

Academic Journals

• The Lancet Respiratory Medicine
• Journal of Thoracic Disease
• Chest (American College of Chest Physicians)
• European Respiratory Journal
• American Journal of Respiratory and Critical Care Medicine
• Journal of Clinical Oncology

Reputable Newspapers

• The New York Times – Health Section
• The Guardian – Health & Science
• The Washington Post – Health
• BBC News – Health
• Financial Times – Health & Science

Public Domain Resources

• U.S. National Library of Medicine
• National Institutes of Health Data Sharing Repositories
• Open Access Journal of Cancer Research
• Global Health Observatory (GHO) Data – WHO

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years